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Golden Rice: A Case Study in Intellectual
Property Management and International
Capacity Building
Stanley P. Kowalski & R. David Kryder

*

Introduction
In order for agricultural biotechnology (agri-biotech) 1 to play a

2
larger role in the development of sustainable agricultural systems,

intellectual property (IP) rights management must be addressed. These
issues are not limited to developing countries. With increased
globalization, the management of agri-biotech IP rights affects both

developing and industrialized countries. In industrialized countries, for
example, IP rights risk management entails protection of inventions via

strong patent portfolios. For developing countries, IP rights risk
management includes the acquisition of rights requisite for the use of
inventions essential to the basic welfare of the population. Strategies are

needed to bridge these disparate IP management paradigms to
facilitate the successful transfer of the agri-biotech from an
industrialized country source to a developing country recipient.
*
Stanley Kowalski was formerly with The International Service for the Acquisition of AgriBiotech Applications at Cornell University, Ithaca, NY. He is currently a J.D. student at
Franklin Pierce Law Center, Concord, NH. E-mail: kowalski3@verizon.net.
R. David Kryder is with The Strategic World Initiative for Technology Transfer,
International Programs, College of Agricultural and Life Sciences at Cornell University, Ithaca,
NY. E-mail: rdkl l @cornell.edu.
Nothing in this paper constitutes a legal opinion and the authors recommend that the
advice of a qualified attorney be obtained to assure appropriate counsel in completing a
freedom to operate review.
I Agri-biotech, as used in this article, includes the use of biotechnology for the development
of genetically modified plants and microorganisms, associated molecular biology (i.e.,
manipulation of DNA and proteins), cell, tissue, and organ culture. See Robert P. Tengerdy &
George Szakacs, Perspectives in Agrobiotechnology, 66 J. Biotechnology 91 (1998).
2
The World Commission on Environment and Development has defined sustainable
development as "development that meets the needs of the present without compromising the
ability of future generations to meet those of the future." See Cai Yunlong & Barry Smit,
Sustainability in Agriculture: A GeneralReview, 49 J. Agric., Ecosystems & Env. 299 (1994).
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This paper examines IP management linked to agri-biotech
products. Further, this paper examines Golden Rice, a genetically
engineered rice strain that accumulates beta-carotene (i.e., pro-vitamin
A) in the endosperm tissue of grain, as a case study for IP management,
with emphasis on the international movement of agri-biotech from
industrialized to developing countries. 3 Topics discussed include: the
application of agri-biotech to international development; the challenge
of transferring this technology from industrialized to developing
countries; a method for evaluating the IP constraints impinging on the
deployment of Golden Rice; industrialized/developing country
perspectives vis-h-vis IP rights management; six shorter-term options for
the management of IP connected to Golden Rice; and a longer-term
proposed path to sustainable transfers of agri-biotech products.
Background
Six factors continue to pressure global agricultural production
capacity: a rapidly expanding global population; an increasing demand
for water resources; the depletion of quality water resources; the decline
in arable land resources; pressure on crop production by diseases, pests
and unfavorable climatic conditions; and the ever-increasing demand
for quality food products. In developing countries the situation is
4
especially critical.
Historically, the "Green Revolution" 5 of the 1960s and 1970s
effectively addressed pressing food concerns of that time. This was
3
For a definition of "developing countries," see World Economic and FinancialSurveys,
World Economic Outlook (May 1999) (available at <http://www.imf.org/external/pubs/ft/
weo/1999/01/>).
Yeshwant L. Nene, Sustainable Agriculture: Future Hope for Developing Countries, 18
Canadian J. Plant Pathology 133 (1996) (The global population is projected to be 6.3 billion in
the year 2000, 8.3 billion in 2020, and 12 billion in 2050, with disproportionate growth in
developing nations. As applied to arable land, resources are estimated at seven million hectares
annually, due to non-sustainable farming practices. A large part of this is linked to the building
of roads, parking lots, buildings, etc., that is, the "development" of cropland into paved
surfaces.); John C. Rodda, Guessing or Assessing the World's Resources?, 9 J.Chartered Instm.
Water and Envtl. Mgt. 360 (1995) (Globally, irrigated lands have increased 7.5-fold since
1900. An accurate assessment regarding the depletion of quality water resources, however,
remains problematic); David Pimental et al., Environmental and Economic Costs of Soil
Erosion and Conservation Benefits, 267 Sci. 1117 (1995) (As applied to the decline in arable
land resources, an estimated twelve million hectares are lost annually).
5
Dave Hoisington et al., Plant Genetic Resources: What Can They Contribute Toward
Increased Crop Productivity?, 96 Proc. Natl. Acad. Sci. U.S. 5937 (1999).
4
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accomplished primarily via conventional plant breeding and improved
crop management practices. Of particular importance to the Green
Revolution were the activities of the Consultative Group on
International Agricultural Research (CGIAR). 6 The CGIAR has
traditionally been a primary source/conduit of agricultural science and
technology for the developing world. 7 However, since many agribiotech discoveries and applications are protected by their
industrialized country owners, it is difficult for CGIAR to legally
distribute these to its developing world clients. Indeed, CGIAR has
only recently begun major agri-biotech research. 8
Agri-biotech has considerable potential for contributing to
sustainable agricultural systems in developing countries. 9 Therefore, it
is seen as an innovative approach to circumvent starvation, i.e., a
"Second Green Revolution." 10 However, unlike the agronomic
approach of the "First Green Revolution," agri-biotech is very
expensive. Millions of scientific research hours and dollars go into the
production and release of agri-biotech products. Therefore,
organizations 1 1 that produce and own agri-biotech products have
surrounded their discoveries with IP protection (patent portfolios).
6
Dennis T. Avery, Food Production: The Success of the International Agricultural
Research Centres, Assessments and Research Report, Bureau of Intelligence and Research, U.S.
Department of State (No. 751-AR). Established in 1971, the Consultative Group on
International Agricultural Research (CGIAR) is an informal association of 52 public and private
sector members that supports a network of sixteen international agricultural research centers.
These are distributed around the globe, in the centers of genetic diversity for their respective
mandated crops, for example, International Potato Center in Peru for potatoes, International
Rice Research Institute in the Philippines for rice, Centro Internacional de Agricultura Tropical
in Colombia for beans. The World Bank, United Nations Food and Agriculture Organization,
United Nations Development Program, and United Nations Environment Program are cosponsors of the CGIAR. The mission of the CGIAR is to contribute, and promote through its
research, sustainable agriculture for food security in developing countries. See
<http://www.cgiar.org/>.
7
Deborah A. Rose, Changing Relationships in Technology Transfer to the Third World:
Case Study of Biotechnology in Agriculture, 11 Rutgers Computer & Tech. L.J. 531 (1985).
8 Janet Bell, A Greener Than Green Revolution?, 15 Seedling 8 (1998).
9
Ismail Serageldin, Biotechnology and Food Security in the 21st Century, 285 Sci. 387
(1999).
10 Gordon Conway, Green Revolutionary, Bus. Week 191 (Nov. 16, 1998).
11 Multi-national corporations, university laboratories, private foundations, and government
laboratories (e.g., USDA).
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Increasingly, agri-biotech is owned by private sector
corporations. 12 The proportion of global agri-biotech research and
development expenditures by the private sector has grown from
approximately 65% in 1994-1995 to 80-85% in 1999.13 Hence, with
so many agri-biotech products subject to IP protection, their
commercial distribution to the developing world poses significant
challenges. Corporations with substantial agri-biotech property
portfolios are understandably reluctant to donate these products to
developing countries which frequently lack enforceable IP protection
and management capability. Corporations justifiably fear that such
humanitarian acts might establish, or at least strengthen a competitor.
Developing countries would likely benefit from cutting-edge agribiotech applications, most of which are the property of industrialized
country-based corporations. However, many of these same developing
countries are currently incapable of protecting or managing such
property rights. Therefore, to develop and maintain international agribiotech transfer, industrialized and developing countries need to
cooperatively implement manageable systems of IP protection. As a
critical component of this strategy, developing countries need to
implement appropriate IP policies and effective enforcement
procedures.
Golden Rice
Genetic engineering of crops has predominantly been in the
production side (e.g., herbicide tolerance, insect resistance, virus
resistance, fungi resistance), and less on the consumer side. 1 4 These
15
first generation transgenic crops, targeted more towards the farmer,
12

Clive James, Agricultural Research and Development: The Need for Public-Private

Sector Partnerships, Issues in Agriculture 9 (The Consultative Group on International
Agricultural Research, World Bank 1996).
13 Kandukuri V. Raman & David W. Altman, Biotechnology Initiative to Achieve Plant
Pest and Disease Resistance, 13 Crop Protection 591 (1994); Steven P. Briggs, Plant
Genomics: More than Food for Thought, 95 Proc. Nati. Acad. Sci. 1986 (1998); Gabrielle J.
Persley, Agricultural Biotechnology and the Poor: Promethean Science, Agricultural
Biotechnology and the Poor: Proceedings of an International Conference 3 (CGIAR 2000).
14 Adriana Cristina Alves et al., Plant Transformation: Advances and Perspectives, 56
Scientia Agricola 1 (1999).
15 Jim M. Dunwell, Transgenic Crops: The Next Generation, or an Example of 20/20
Vision, 84 Annals Botany 269 (1999).
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represent attempts to reduce input costs. However, second generation
transgenic crops embody "value-added innovations." 1 6 Golden Rice,
as a second generation transgenic, is a pioneering step in the use of agribiotech to produce a significant impact at the consumer level, more
17
specifically in developing countries.
In Golden Rice, the successful engineering of the carotenoid
biosynthetic pathway (i.e., genes) in the rice endosperm, with the
subsequent expression of pro-vitamin A (i.e., beta-carotene), represents
a remarkable technological accomplishment. Specifically, this is due to
the utter complexity of the carotenogenic pathway, as well as the
interrelated nature of plant metabolic systems. 1 8 This technical and
scientific complexity clearly indicates the IP/technical property (TP) 1 9
complexity of Golden Rice, which, in turn, makes its transfer to the
developing world such a challenge.
Golden Rice has significant potential for the alleviation of chronic
20
vitamin A deficiency (VAD) throughout the developing world.
VAD is a serious public health problem, 2 1 with worldwide estimates
16 Gordon C. Rausser & Arthur A. Small, The Economic Value of Patents, Licenses, and
Plant Variety Protection,The Giannini Foundation of Agricultural Economics, Working Paper
(June 1996).
17 Xudong Ye et al., Engineering the Provitamin A (beta-carotene) Biosynthetic Pathway
Into (carotenoid-free) Rice Endosperm, 287 Sci. 303 (2000).
18 Gerhard Sandmann, Carotenoid Biosynthesis and Biotechnological Application, 385
Archives Biochemistry Biophysics 4 (2001); Trevor Walworth Goodwin & Eric Ian Mercer,
Introduction to Plant Biochemistry (2d ed., Pergamon Press 1983).
19 Proprietary property, or proprietary science, as used throughout this paper, is comprised of
intellectual property (IP) and technical property (TP), sometimes referred to as "tangible
property." IP is taken to mean, without limitation, IP rights, including patent rights, plant
variety protection certificates, unpublished patent applications, and any inventions,
improvements, and/or discoveries that may or may not be legally protectable, including knowhow, trade secrets, research plans and priorities, research results and related reports, statistical
models, computer programs, related reports, market interests, and product ideas. TP is taken
to mean, without limitation, tangible property such as computer software, germplasm and the
biological materials and derivatives thereof, and related materials. As a hypothetical example of
TP and IP, a plasmid-vector construct transferred from laboratory A to laboratory B, under a
Material Transfer Agreement (MTA), is owned as a TP by laboratory A, and the MTA may
stipulate restrictions on usage by laboratory B. However, IP rights owned by third parties may
be embedded in the construct (e.g., gene promoters, selectable markers).
20 Ingo Potrykus, Golden Rice and Beyond, 125 Plant Physiology 1157 (2001 ); see Ye et
al.,
supra n. 17.
21 Alfred Sommer, Vitamin A Deficiency and Its Consequences: A Field Guide to
Detection and Control (3d ed., World Health Organization 1995).
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of 100 to 200 million children affected.2 2 In 1989, up to 1.2 million
deaths of preschoolers were attributed to VAD. 2 3 Five hundred
thousand children are permanently blinded every year due to
xerophthalmia (severe VAD). 2 4 These children die at nine times the
rate of healthy children. 2 5 Between one and three million children die
of infections every year, preventable if the children had not been
deficient in vitamin A. 2 6
Golden Rice represents the vanguard for a new class of agri-biotech
products, and a model case study for the effective, efficient, and
equitable distribution of an agri-biotech product from industrialized
country sources to developing countries where such products are most
needed. Unresolved IP/TP rights constraints present the risk of
complicating international deployment of Golden Rice. This truly is a
human dilemma in that restrictions on the distribution of beneficially
appropriate, value-added, genetically engineered crops to developing
countries may affect the welfare of millions of lives, and, in the case of
Golden Rice, millions of children. For this reason, management of IP
and TP issues associated with Golden Rice have potentially far-reaching
ramifications.
Methodology
Pragmatic management of the international transfer of IP/TP rights
associated with an agri-biotech product (e.g., Golden Rice), begins with
a systematic product clearance (PC). 2 7 This is a para-legal document
22

Jean H. Humphrey et al., Vitamin A Deficiency and Attributable Mortality Among

Under 5-Year-Olds, 70 Bull. of the World Health Org. 225 (1992).
23 Jenny Cervinskas & Mahshid Lofti, Vitamin A Deficiency: Key Resources in Its
Prevention and Elimination, The Micronutrient Initiative Information Paper No. 1 (2d ed.,
1996) (available at <http://www.micronutreint.org/publications/vadkey.shtml>).
24 Gerald F. Combs, The Vitamins, FundamentalAspects in Nutrition, and Health (2d ed.,
Academic Press 1998).
25 Id.
26

Barbara A.

Underwood,

Prevention of Vitamin A

Deficiency, Prevention of

Micronutrient Deficiencies, Tools for Policymakers and Public Health Workers (C.P. Howson
et al. eds., National Academy Press 1998).
27 See John H. Duesing, Managing a Product Clearance Process Toward Freedom-toOperate, Proceedings of the American Seed Trade Association Annual Meeting (1996)
(publicized with permission of J.H.D. and A.S.T.A.) (available at <http://www.amseed.com/
index.html>). In order to manage the IP and TP attached to agri-biotechnological applications,
a systematic PC process leading to freedom-to-operate (FTO), as clearly defined by John H.
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produced in large measure by scientists who clearly understand the
inherent technological complexities of the product. The PC involves a
detailed listing and analysis of all aspects of the agri-biotech product.
The PC is a detailed dissection, referred to in this paper as a "product
deconstruction," into the product's essential components. The PC is
based on, and developed from, a series of questions such as: what are
the methods and procedures that went (will go) into producing the
agri-biotech product; what are its principal components; what are the
essential ingredients that constitute each principal component; what are
the IP/TP rights that may be attached to each component and its
ingredients; and who seems to own the IP/TP rights of each
component and each of its ingredients?
Ideally, the PC describes and analyzes every essential aspect of the
product. It must be as comprehensive as economically possible. Product

deconstruction can take place either when the product is in the planning
stage, when the research and product development is underway, or
when the agri-biotech product, such as Golden Rice, is ready for
distribution. Further, once the product is in the stream of commerce, it
is prudent to produce an annual PC update because of the changing

IP/TP rights landscape.
Duesing, is essential. According to Duesing, FTO is "the ability to undertake research projects
and/or commercial development and sales activities involving a particular technology or
product with minimal risk of infringing the unlicensed patent or tangible property ownership
rights of another party." Duesing adds that "[a]n FTO opinion is prepared by patent counsel
and reflects counsel's legal determination regarding FTO for a particular commerciallydirected activity, including research." To reach an FTO opinion, a PC is necessary. As J.
Duesing explains, "PC is a process that tracks FTO and other critical issues for a product under
development and prior to and after commercial sale. Itis undertaken at request of counsel as
part of the total assessment of whole product FTO in order to support company decisions
regarding product development and the sale of each product. All information pertaining to a
given product (i.e., technical, patent, license, FTO options) is assembled to document the
organization's full knowledge, completed and pending actions, and decisions relating to wholeproduct FTO." PC entails a detailed dissection of the product into the essential ingredients
involved in its development. As defined by Duesing, PC "defines the technical content of the
product or a potential product. A product or technology profile is prepared that includes 1) all
"ingredients" incorporated into the product; 2) all processes used to achieve the product; 3) any
specific combination of ingredients and processes used to achieve the whole product. The
profile details every essential aspect of the product." This process of dissection is called
"deconstruction." Although all of the relevant patents are searched, the TP also must be
adequately monitored and assessed. The important point here is that (as per Duesing) "[elach
company should monitor carefully its acquisition of tangible materials from other parties, to
ensure that the material is obtained with the appropriate agreement to show that the company
has legitimate control of the tangible material, and that there are no restrictions on its
commercial use."
13 Risk. Health, Safety & Environment 47 [Spring 2002]

Generally, it is in any organization's strategic best interest to
conduct a product deconstruction at the earliest possible phase in
product development. When alternatives exist, this process can help
research scientists focus only on those items where IP is most readily
available. In some cases, the thrust of the scientific research may be to
invent around a competitor's IP position. Producing a timely, proactive
PC is a wise resource expenditure. It permits an early assessment of the
IP landscape and allows management decisions to be made well in
advance regarding which components, technologies, and processes are
best to incorporate into the product under development, in order to
avoid using those which are not owned or cannot be readily licensed.
28
A patent attorney can then draft a freedom to operate (FTO)
opinion. This is written on the basis of the para-legal PC, the attorney's
thorough search of various patent databases, a review of the applicable
patent claims, an understanding of the appropriate laws, and an analysis
of all the pertinent documents such as Material Transfer Agreements
(MTAs) 2 9 that might impact the product being developed. Finally,
with all of this in place, the patent attorney renders an FTO opinion.
Such an FTO opinion is ideally performed as early as economically
feasible in the product development cycle as a pre-emptive "IP/TP
rights hygiene" review. However, because of the significant resource
28

See the CAMBIA (Center for the Application of Molecular Biology to International

Agriculture) website for useful information on IP issues in agriculture (available at
<http://www.cambia.org. au/main/ip-primerjfto.htm>). Concerning FTO, "Determination of
'freedom to operate' - requires technical knowledge, a broad business overview, detailed

understanding of patent claims in all relevant countries, understanding of markets and national
jurisdictions, and knowledge of litigation and negotiation procedures in relevant jurisdictions.
Our approach is for specialists with scientific and patent skills to work with researchers and

business people to analyze relevant intellectual property and to develop appropriate strategies
that will allow innovations to be implemented effectively." See generally Eran Binenbaum et
al., South-North Trade, Intellectual Property Jurisdictions and Freedom to Operate in
Agricultural Research on Staple Crops, International Food Policy Research Institute,
Environment and Production Technology Division (2000).
29 An MTA is a type of contractual agreement that offers a variety of proprietary protection,
frequently for materials (e.g., TP) not covered by patents. In agricultural research, MTAs are
used in the transfer of plant genetic resources, plasmid constructs, transformation vectors, etc.
See Michael Blakeney et al., Intellectual Property Rights and Agricultural Biotechnology, in
Managing Agricultural Biotechnology: Addressing Research Program Needs and Policy
Implications 209 (Joel I. Cohen ed., CABI Publishing 1999); see also Tai-Sen Soong,
Industrial Research and Business Development: Experiences From the Singapore Institute of
Molecular Agrobiology, in Managing Agricultural Biotechnology: Addressing Research
Program Needs and Policy Implications 272 (Joel I. Cohen ed., CABI Publishing 1999).
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requirement for such a FTO review, every agri-biotech R&D
organization will be limited in the number of FTO opinions that it is
willing to initiate. Further, because nearly all statutory protection is
based on national law rather than international law, a separate FTO
review is required for each country where a product will be made, used,
imported, or sold. In addition, because new patents are continually
issuing while others are expiring, the IP landscape is in continual flux.
An FTO opinion is therefore a snapshot, and thus, is a risk management
opinion regarding a particular product at a particular time for a
particular country.
In a product deconstruction, it is vitally important to distinguish
between IP rights and TP rights. This cannot be overemphasized. All IP
issues need to be searched and all TP concerns must also be accurately
identified and assessed. The sources of TP from other parties must be
clearly documented to ensure that such TP has been obtained under an
appropriate MTA. It is similarly important to assure that the source of
the TP had a legitimate right to distribute that TP. A review of the
MTAs will clarify the legitimate ownership of such TP as was used to
produce the new agri-biotech product and will lay the groundwork for
knowing if the developing country scientists will have commercial use
and/or distribution rights.
As a part of IP/TP rights analysis attached to a new agri-biotech
product, germplasm rights must be thoroughly investigated. This
entails reviewing the source of all germplasm that is used to produce the
new product. It must be determined if germplasm is protected, for
example, by plant variety protection, a plant patent, or a utility
patent. 3 0 The germplasm variety, inbred, or breeding population used
to develop a transgenic product represents the foundation of that
30 Janice A. Kimpel, Freedom to Operate: Intellectual Property Protection in Plant Biology
and its Implicationsfor the Conduct of Research, 37 Annual Rev. Phytopathology 29 (1999)
(A form of protection for plant varieties, similar to a patent, but with some significant
exemptions. The U.S. Plant Variety Protection Act of 1970, amended in 1994, provides plant
variety protection certificates for sexually and clonally, i.e., tuber-bearing, crops) (Expansion of
the U.S. patent law in 1930, which provided provisions for the patenting of asexually
propagated plants excluding uncultivated and tuber-propagated species); Frederic H. Erbisch &
Carlos Velazquez, Introduction to Intellectual Properties, in Intellectual Property Rights in
Agricultural Biotechnology 3 (Frederic Erbisch & Karim Maredia eds., CABI Publishing 1998)
(An exclusive right given to an inventor to exclude all others from making, using, and/or selling
the invention. The right the inventor possesses depends on which country issued the patent.
Claims on utility patents relating to plants may extend to germplasm).
13 Risk Health, Safety & Environment 47 [Spring 2002]

product. A detailed tracing of plant pedigrees with a determination of
3
any rights or licenses attached to the germplasm (e.g., "bag tags"), 1
that impose any limitation on the use of and/or distribution of seeds
and their progeny, must be duly carried out far in advance of product
introduction. This analysis of the source of all germplasm must be
included in the FTO opinion.
A product deconstruction of Golden Rice is presented in the
following section.
Summary of Analyses
The overall product deconstruction of Golden Rice3 2 tentatively
identified 15 TP components and 70 patents (with 31 assignees) 3 3 of
potential relevance. A great deal of this complexity stemmed from
Golden Rice being a multi-transformant. Genes (enzymes/enzymatic
activities/steps) required to catalyze four steps in the carotenogenic
biosynthetic pathway were successfully engineered into rice seed
endosperm. 3 4 Each of these, in turn, was assembled into a genetic
transformation construct, complete with plant transcription promoter
and termination sequences, as well as appropriate selectable markers. In
the product deconstruction of Golden Rice, four major components
were examined:
1. Plant/seed source, the rice race japonica (TP309), which is a
35
tropical variety adapted to Taiwan;
31

Peter J. Goss, Guiding the Hand That Feeds: Toward Socially Optimal Appropriability

in Agricultural Biotechnology Innovation, 84 Cal. L. Rev. 1395 (1996).
32 For a detailed description of the product deconstruction and IP/TP analysis of provitamin A rice (i.e., Golden Rice), see R. David Kryder et al., The Intellectual and Technical
Property Components of pro-Vitamin A Rice (GoldenRiceTM): A Preliminary Freedom-ToOperate Review, ISAAA Briefs No. 20, at 56 (2000).
33 It is of interest to note that every primary assignee was situated in an industrialized
country (i.e., Belgium, France, Germany, Israel, Japan, Netherlands, Switzerland, U.K., and the
U.S.).
34 See Ye et al., supra n. 17. Phytoene synthase (enzyme) = psy (daffodil gene); Phytoene
desaturase (enzyme) = crtl (bacterial gene); Zeta-carotene desaturase (enzyme) = crtl (bacterial
gene); Lycopene cyclase (enzyme) = Icy-b (daffodil gene).
35 For a discussion of the IP issues currently being debated with regard to the CGIAR
germplasm collections, see Susan H. Bragdon, Recent Intellectual Property Rights
Controversies and Issues at the CGIAR, in Agriculture and Intellectual Property Rights,
Economic, Institutional and Implementation Issues in Biotechnology 77 (Vittorio Santaniello
et al. eds., CABI Publishing 2000).
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2. Gene constructs, e.g., cloning vectors (pBluescriptKS);plant
transformation vectors (pBinl9hpc, pZPsC, pZLcyH);
3.Transformation (Agrobacterium-mediated), tissue culture
(scutella culture), plantlet regeneration (NB medium), as well as
other techniques; and
4. DNA amplification, the polymerase chain reaction (PCR),
and the enzyme that catalyzes this reaction (Thermus aquaticus
"Taq" polymerase).
In turn, each of these major component categories was further
dissected to yield deeper layers of complexity in the product. For
example, the plant transformation vector pBinl9hpc is a complex
construct, with numerous subcomponents and processes integral to its
generation, among these: the plant gene promoter CaMV35S; the seed
endosperm specific gene promoter Gtl; the selectable marker nptII
(kanamycin resistance); the pea Rubisco small subunit transit peptide
(DNA); the selectable marker aphIV (hygromycin resistance); the
carotenoid biosynthetic gene psy (phytoene synthase); the carotenoid
biosynthetic gene crtI (phytoene desaturase); Agrobacterium-mediated
transformation; and co-transformation technology. Each of these
components might have IP and/or TP rights attached to it, potentially
affecting the eventual FTO opinion. IP and TP issues potentially
constraining the distribution of Golden Rice will vary on a country-tocountry basis.
The product deconstruction of Golden Rice, as well as any similarly
complex product, is additionally challenging due to the added factor
of uncertainty. Four types of uncertainty are considered here:
(1) Complexity of assignees on patents. In the case of Golden
Rice, thirty-one were tentatively identified. 3 6 However, it is important
to note that these are the original assignees as listed on the patent cover
pages. Because the corporate world is in a constant state of change,
determining precisely which entity has the right to grant licenses for a
particular component or process is not always straightforward. Indeed,
as companies re-structure, sell/assign patents, or grant licenses, with or
without the right to sub-license, the degree of uncertainty increases.
36

See Kryder et al., supra n. 32.
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(2) Absence of MTAs for TP. If a MTA for a specific TP
component is not available, this does not mean that distribution of that
component is without restrictions. On the contrary, such absence of a
MTA probably signals the need for greater caution and deeper
investigation due to the added uncertainty which this produces.
Although most agri-biotech research facilities in industrialized countries
have functioning technology transfer offices, it is not uncommon for
researchers to bypass the procedures set up by these offices. For
example, scientists, particularly those at public sector research facilities,
have long exchanged TP components (e.g., plasmid constructs, gene
promoters, antibodies) very casually. Therefore, the absence of a MTA
for a particular TP component should be heeded as a warning sign and
not some sort of "fortuitous convenience."
(3) Import/export issues. The potential impact of international
movement (import/export) of Golden Rice adds an additional layer of
complexity to the international IP landscape. For example, if a product
is produced outside the U.S. using an unlicensed U.S. patented process,
U.S. law prohibits the importation of such products back into the
U.S. 3 7 Similar provisions are incorporated into the language of the
Trade-Related Aspects in Intellectual Property Property Rights
agreement.38 As the IP landscape evolves, worldwide IP
harmonization proceeds, and the globalization of biotechnology
extends more and more to developing countries, this situation will
39
require continual and careful attention.
(4) Static (narrow time-frame) vs. dynamic (broad time-frame)
PC analysis. There is uncertainty and attendant risk associated with
static versus dynamic PC analysis. Binenbaum et al. have observed that
since most of the IP present in Golden Rice is not protected in the
majority of regions where it is to be distributed, the PC analysis (to the
37
38

See 35 U.S.C. § 271 (g), 287(b), 295; see also <http:llvww.uspto.govl>.
See Trade-Related Aspects in Intellectual Property Rights, § 28(1)(b); see also

<http://www.wto.org/>. Note: Trade-Related Aspects in Intellectual Property Rights
obligations are binding on any WTO signatory country.
39 David K. Y. Tang & Mary K. Williamson, Intellectual Property Rights, in The

International Lawyer's Deskbook 109 (ABA Sec. Intl. L. Prac. 1996); Edgar J. DaSilva,
Review: Biotechnology: Developing Countries and Globalization, 14 World J. Microbiology

Biotechnology 463 (1998).
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extent performed for Golden Rice) is largely not applicable. 4 0 In a
static time frame, this is a correct and coherent observation. However,
when reconsidered within the context of the dynamic nature of the
international iP landscape, the uncertainty of future changes and
developments, whether it be five, ten, or twenty years ahead,
predominates. This persistent level of uncertainty, therefore, gives good
reason for a dynamic, comprehensive, and global PC analysis. Hence,
having better knowledge of the global IP landscape facilitates informed
risk assessment (i.e., a greater number of potentialities can be
anticipated). The two paradigms (static and dynamic) are not mutually
exclusive, rather, they are two legitimate viewpoints. The static
paradigm is an analysis of a "snapshot," and the dynamic paradigm
relates more to the complex and fluid realities of international
development and the harmonization of global IP rights systems.
Related to this is the viewpoint that the entities which produce/own the
most advanced agri-biotech applications released in industrialized
countries will not seek IP rights protection on these products in
developing countries. As a result, due to this lack of strong IP rights
protection, developing countries would have a distinct advantage to be
able to access (i.e., "pirate") these new products. Indeed, in the short
term this may be true. However, a longer-term perspective suggests that
such an approach would bring developing countries the greater risk of
only obtaining second-tier products, rather than those that are truly
cutting-edge. Unfortunately, this limitation would principally impact
the developing countries that can benefit most from products such as
Golden Rice.
Options
The preliminary PC analysis, as summarized in this paper, was
conducted to better understand the current IP/TP rights situation so
that options and alternative future strategies can be discussed and
developed. Resource-poor farmers and rice consumers in developing
40 See Binenbaum et al., supra n. 28; Kryder et al., supra n. 32 (Of the approximately 70
patents and PCT applications tentatively identified as potentially related to Golden Rice, the
number of PCT applications listing major rice producer developing countries as designated
states represented a subset: China on eleven, India on five, Indonesia on six, Vietnam on eight,
and Sri Lanka on eleven PCT applications, respectively).
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countries where rice is a staple are intended to be the ultimate
beneficiaries of the deployment of Golden Rice. This desired end
result, of providing farmers and consumers with a superior product, is
the same regardless of the type of donor/recipient entities (i.e., private
corporate, public university, national agricultural research center,
philanthropic) that may be involved. The means and acceptable level of
risk will likely vary depending on the nature of these organizations.
Hence, as a risk management tool, this study can serve as a template
for an organization's assessment and management of risk (i.e., the
degree of risk that it is willing to assume). What we present here,
therefore, is a framework within which an IP/TP risk management
course of action can be mapped out, taking advantage of a maximum
amount of data that can realistically be assembled, analyzed, and
organized. Furthermore, since numerous types of organizations are
potentially involved and the term "developing country" is a broad
categorization for many different countries, each with unique
circumstances, a blanket recommendation is not possible.
Capacity building in IP/TP risk assessment and management is also
of critical importance. 4 1 In that respect, the authors present six
alternative options regarding the IP/TP risk management of Golden
Rice. 4 2 Then it is hoped that, as full partners, developing and
industrialized countries can proceed with deliberation and the decision
to find the most appropriate process for the development, distribution,
and production of agri-biotech products such as Golden Rice.
41

Karim M. Maredia & Frederic H. Erbisch, Capacity Building in Intellectual Property

Management in Agricultural Biotechnology, Intellectual Property Rights in Agricultural
Biotechnology 49 (Frederic H. Erbisch & Karim M. Maredia eds., CABI Publishing 1998).
Capacity building is a phrase frequently used in international development literature, broadly
meaning "the strengthening and/or development of human resources and their institutional

support structures.
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Six previously proposed strategies for an international plant breeder to obtain the processes

and products needed for modern breeding, presented as potential alternatives for consideration,
include: 1) purchasing the necessary licenses; 2) cross-licensing; 3) merging with a holder of
necessary technology; 4) getting a research license; 5) ignoring the problem and hope it will go
away; and 6) making a market segmentation deal. For further elaboration of these strategies,
see Brian D. Wright, International Crop Breeding in a World of Proprietary Technology, in
Agriculture and Intellectual Property Rights, Economic, Institutional and Implementation
Issues in Biotechnology 127 (Vittorio Santaniello et al. eds., CABI Publishing 2000); see
Kryder et al., supra n. 32.
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Option 1: Invent around the current patents. This is an intensive
science and research-based approach, which entails developing and
inventing alternative ways to "regenerate" Golden Rice. This could
involve using alternative biosynthetic genes to engineer rice that
accumulates carotenoids in the seed endosperm, hence an entirely new
invention. For example, genes from plant sources might replace the
bacterial genes, which had been used to originally generate Golden
Rice. However, because it attempts to reduce the reliance on patents
owned by others, this option may, relatively speaking, be too time
consuming or costly, and, for scientific reasons, may be extremely
laborious or not even feasible.
Option 2: Re-design the constructs. This is a product-development
based approach and involves the re-design and re-engineering of the
molecular constructs to purposely avoid certain TP and/or IP
constraints, depending on the language found in relevant patents or
licenses. Redesigning the constructs might involve reassembling the
various molecular pieces found in Golden Rice, with possible
substitutions (e.g., different markers and/or promoters instead of
attempting to obtain these as "pre-assembled" packages). This approach
may be quite effective, but, at best, science is not easily predictable and,
at worst, such an approach will require considerable time (possibly three
to five years).
Option 3: Approach all current IP/TP owners with a request that
they relinquish their proprietary claims.4 3 This is a humanitarian
approach focused on public perception. Public or private statements of
rights abandonment by the certified owners/assignees for each IP/TP
right would eliminate all FTO issues attached to commercial activities
with Golden Rice. This approach, of course, would greatly simplify
licensing negotiations. However, a royalty-free license might still be
required due to various liability/indemnity reasons. Further, such an
43 See e.g. <http:/lwww.cbsnews.comlnowlstory> (Aug. 4, 2000). Monsanto announced it
will give away free licenses to use its patented technology for so-called "golden rice" and other
generically engineered rice varieties that advocates say could save millions of Third World
children.
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approach might work on high profile products like Golden Rice, but
might not provide full freedom to operate for all new agri-biotech
products.
Option 4: Ignore all IP and TP rights claims and just produce and
distribute the agri-biotech product. This is a short-term perspective
with the lowest initial cost. However, longer-term difficulties are likely
to ensue if this option is followed. For example, lawsuits, delays of
product distribution, limitations on importation capabilities, and poor
relations with IP/TP owners are some of the unpleasant possibilities that
might flow from this option.
Option 5: Seek licenses from all of the IP and TP rights owners.
This is the licensing approach. It would require the acquisition of an
appropriate license for each individual IP/TP right connected to
Golden Rice. The nature of the license negotiated would be
determined by the needs of the potential licensee, as well as by what the
licensee and licensor mutually determine to be required. This is the
safest route to distribution, and ensures good, long-term relationships
with the IP/TP rights holders. However, this option is complex, costly,
and potentially very time consuming. Furthermore, given the relatively
limited legal and governmental infrastructure in many developing
countries, the owners of the IP/TP rights may be reluctant to
consummate such licenses until the recipients exhibit additional IP
rights management capacity.
Option 6: A mix of all of the options 1 to 5. This represents a
pragmatic, realistic approach to obtaining full FTO for Golden Rice.
Due to the flexibility imparted by taking advantage of the numerous
available options, this is the most effective route for the distribution of
Golden Rice. However, it still requires that both the recipients of
Golden Rice and the donors understand and recognize the issues that
are involved.
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Discussion

Sustainable,Equitable,and InternationalAgri-biotechTransfers:
ManagingRisks and Maximizing Opportunities
Despite current disagreements over the appropriateness of various
proposed IP regimens and inconsistencies in enforcement of IP laws
throughout the developing world, the inexorable movement towards
global harmonization of IP rights systems appears highly likely.4 4 This
45
trend is linked to the continuing expansion of the global economy.
As the legal norms for IP rights protection become progressively more
consistent at the international level (i.e., the international deployment
of IP systems similar to those that have proven to be successful in
industrialized countries) trans-national corporations are likely to
increase operations in developing countries. 4 6 Worldwide recognition
of, and adherence to, IP rights harmonization should facilitate the
participation of many countries as full partners in the global
economy. 4 7 For developing countries, agricultural improvement is a
top priority.
When considering the global harmonization of IP rights protection,
certain realities must be appreciated. Developing countries will change,
but it is critical to recognize that such change is gradual, and proceeds
44 Lorna Brazell, Strategies for Minimizing IP Risks, 120 Patent World 19 (2000); see
DaSilva, supra n. 39; see Tang & Williamson, supra n. 39.
45 John G. Fernald & Victoria Greenfield, The Fall and Rise of the Global Economy, 164
Chi. Fed Ltr. 1 (2001).
46 The Nuffield Council on BioEthics, May 1999, Genetically Modified Crops: The Ethical
and Social Issues, The Nuffield Foundation, London.
47 This viewpoint represents an optimistic affirmation of the value of IP rights in international
agricultural development. The polarity of viewpoints has been summarized by Lesser et al.:
"One school of thought maintains that developing countries with effective IPRs will attract
more research and development (R&D) spending, particularly from the private sector. A
second widely held view disputes this conclusion, maintaining that, at the extreme, IPR
amounts to economic colonialism." William Lesser et al., Intellectual Property Rights,
Agriculture, and the World Bank, in Intellectual Property Rights in Agriculture, The World
Bank's Role in Assisting Borrower and Member Countries 1-21 (Lele et al. eds., The World
Bank 1999). In a similar manner, Ismail Serageldin states that: "Supporters of patenting point
out that if the private sector is to mobilize and invest large sums of money in agrobiotechnology
R&D, it must protect and recoup what it has put in. On the other side of the argument is fear
that patenting will lead to monopolization of knowledge, restricted access to germplasm,
controls over the research process, selectivity in research focus, and increasing marginalization of
the majority of the world's population." See Serageldin, supra n. 9.
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stepwise. In this context, a "three-stage model" of IP rights evolution in
48
developing countries is useful:
1. The first stage is in those countries with the lowest level of
economic development. In such countries, IP rights protection is
not an issue because the economic and technological infrastructure
is below the basic requirement needed for utilization of
technological advances.
2. The second stage is in those countries that can utilize
advanced technologies, but the economic level of development, or
the domestic supply of capital, is still low. In these circumstances,
technology piracy routinely occurs.
3. The third stage is in those countries where public and
private entities can generate world-class inventions. Here, IP rights
protection becomes essential in order to credibly and productively
participate in the international economic community, with
reciprocal recognition and enforcement of IP rights.
Coupled with the global harmonization of IP rights is the
inexorable international spread of biotechnology into agricultural
systems. 4 9 The global planting of transgenic crops continues to
increase. In industrial countries where the total transgenic acreage is
currently concentrated, the rate of deployment of transgenic crops
currently appears to be leveling off. However, in developing countries,
the planting of transgenic crops is increasing significantly. 50 In both
industrialized and developing countries where transgenic crops have,
until recently, been primarily agronomic (crop-protection) based, valueadded products with broad application such as Golden Rice are on the
51
horizon.
48

Stefan Kirchanski, Protection of U.S. Patent Rights in Developing Countries: U.S. Efforts

to Enforce PharmaceuticalPatents in Thailand, 16 Loy. L.A. Intl. & Comp. L.J. 569 (1994);
see also Lesser et al., supra n. 58. (a somewhat parallel model is discussed: "Sherwood (1997)
distinguishes between three levels of IPR protection: (1) nonrobust, (2) TRIPs-compatible, and
(3) investment stimularing/robust.").
49 See Rausser & Small, supra n. 16.
50 Clive James, Global Status of Commercialized Transgenic Crops: 2000, ISAAA Briefs
No. 21 (ISAAA 2000). The global increase of transgenic crops between 1999 and 2000 was
11%, equivalent to 4.3 million hectares. Of this increase, 84% was in developing countries.
51 See Dunwell, supra n. 15; Potrykus, supra n. 20.
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Due to the differing perspectives and circumstances of
industrialized and developing countries, establishing a foundation for
fair and equitable negotiations vis-4-vis IP rights is not simple. Many
developing countries may not consider the legal recognition of foreign
patents to be important. 5 2 When negotiating license terms, developing
countries are usually at a disadvantage because key personnel are
inadequately trained 5 3 and most developing countries have an
54
insufficient number of licensing officials and IP managers.
Therefore, in such developing countries, since agriculture is considered
integral to national sovereignty, piracy of agri-biotech is more likely to
be considered justifiable. 5 5 The unfortunate legacy of colonialism
complicates the situation even more. 5 6 From the industrialized
country perspective, investors view the IP portfolio of a company as an
absolutely essential component. 5 7 The system of IP rights protection
of a potential partner influences technology transfer and investment
decisions. 5 8 Therefore, industrialized countries firmly believe that a
healthy patent system encourages invention/investment in a sustainable
fashion. 5 9 Notwithstanding the different viewpoints between
developing and industrialized countries, improved IP rights
harmonization appears to be integral to the economic development of
all countries. 6 0 Hence, if IP issues are adequately addressed,
52 See Kirchanski, supra n. 48.
53
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See Lesser et al., supra n. 47.
See Nuffield Council on BioEthics, supra n. 46.
See Kirchanski, supra n. 48.
Id

57 Cliff D. Weston, Chilling of the Corn: Agricultural Biotechnology in the Face of US.
Patent Law and the CartagenaProtocol,4 J.Small Emerging Bus. L 377 (2000)58 See Lesser et al., supra n. 47.
59 David G. Scalise & Daniel Nugent, International Intellectual Property Protectionsfor
Living Matter: Biotechnology, Multinational Conventions and the Exception for Agriculture,
27 CaseW. Res. J. Ind. L 83 (1995).
60 Id. In addition, Lesser states that "Adequate (IPR) protection is credited with three
benefits: (i) encourages investment and creativity; which in turn (ii). enhances technological
progress, a critical aspect of U.S. competitiveness; and (iii) attract(s) needed foreign' know-how
and investment to developing countries." See William Lesser, Intellectual Property Rights
Under the Convention on Biologica[ Diversity, hi Agriculture and Intellectual Property
Rights, Economic, Institutionaland Implementation Issues in Biotechnology 3.5 (Santaniello et
al. eds., CABI Publishing 2000). For two studies. (using economic models) on the potential
benefits of strengthened IP rights to developing countries, see Robert E. Evensorr, Intellectual
13 Risk: Health, Safety 8r Environment 47 [Sprfng 2002],

globalization presents opportunities to move agri-biotech
internationally, thereby fostering the technological and legal
infrastructure conducive to domestic R&D activities (that is, "homegrown product development") within developing countries.
Within the context of these disparate positions, momentum for
constructive change is essential. Industrialized countries need to
understand the evolutionary process of IP protection in developing
countries and to provide incentives to facilitate accelerated progression
from Stage 1 (i.e., minimal technology infrastructure) to Stage 3 (i.e.,
technology infrastructure with IP protection). 6 1 Correspondingly,
developing countries need to fully recognize the necessity of stable and
enforceable IP systems, which will support the sustainable movement of
advanced agri-biotech into their countries. Under the best of
circumstances, this is a win-win scenario. 6 2 The long-term benefits to
the technology providers (most likely industrialized countries) include:
protection of IP portfolios; protection and expansion of commercial
markets, while providing technology to those who need it most;
improved public perception of trans-national corporations; and new,
sustainable partnerships. The long-term benefits to technology
recipients (mostly developing countries) include: increased agricultural
outputs; improved agricultural products (e.g., Golden Rice); opening of
export markets; access to "hands-on" knowledge and skill of
practitioners of the art; legal access to patented technologies at a more
fundamental level; 6 3 fostering of a national infrastructure for
Property Rights, Access to Plant Germplasm, and Crop Protection Scenarios in 2020, 39 Crop
Sci. 1630 (1999); James R. Markusen, Contracts, Intellectual Property Rights, and
Multinational Investment in Developing Countries, 53 J. Intl. Econ. 189 (2001). For empirical
data supporting the potential benefits of strengthened IP rights to developing countries, see
Keith E. Maskus & Guifang Yang, Intellectual Property Rights, Foreign Direct Investment
and Competition Issues in Developing Countries, 19 Intl. J. Tech. Mgt. 22 (2000); Carlos A.
Primo Braga & Carsten Fink, International Transactions in Intellectual Property and
Developing Countries, 19 Intl. J. Tech. Mgt. 35 (2000). The potential short and long-term
economic impact (e.g., foreign direct investment) of IP rights protection in developing
countries is complex, whereas benefits may be of a primarily dynamic nature, there might also
be some benefit to developing nations in the static perspective.
61 See Kirchanski, supra n. 48.
62

Mary Arends-Kuenning & Flora Makundi, Agricultural Biotechnology for Developing

Countries, 44 Am. Behavioral Scientist 318 (2000) (discussing the benefits to both technology
donors and recipients in the specific case study involving the transfer of viral resistance
technology in potatoes from Monsanto Corp. to Mexico).
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sustainable technology development; fostering of a legal
infrastructure; 6 4 and new, sustainable partnerships.
Golden Rice represents a specific case study/model system of an
agri-biotech product that can be transferred to the developing world.
The genetic engineering of value-added nutritional quality into Golden
Rice is a turning point both scientifically and in terms of international
technology transfer. Scientifically, the engineering of plant (in this case
rice) metabolism to enhance accumulation of carotene is a complex and
pioneering advance. To transfer this promising technology from the
industrialized sources who own it to the developing countries of the
world, where it is most needed, is equally complex. This paper proposes
six short-term strategies for management of IP risk potentially
associated with the international movement of Golden Rice. However,
over the longer term, increased international harmonization of IP laws
and management might serve to ameliorate many of these risks, and
hence facilitate the sustained transfer of Golden Rice as well as future
advances in agri-biotech.

63 David R. Purnell, InternationalImplications of New Agricultural Biotechnology, 25 U.
Mem. L. Rev. 1189 (1995)
64 For a broad discussion on the importance of property rights to the overall betterment of
developing countries and their societies, see Poverty and Property Rights, Economist 20 (Mar.
31, 2001).
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